Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Urogen Pharma Ltd URGN

Healthcare Biotechnology
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:URGN)

New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO®

Business Wire 1 day ago

UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025

Business Wire November 6, 2024

UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference

Business Wire November 5, 2024

UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024

Business Wire October 30, 2024

ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC

Business Wire October 28, 2024

UroGen Announces FDA Acceptance of its New Drug Application for UGN-102

Business Wire October 15, 2024

UroGen Appoints Chris Degnan as Chief Financial Officer

Business Wire October 9, 2024

First Patient Dosed in Phase 3 Clinical Trial of UGN-103, a Next Generation Mitomycin-Based Formulation in Development for the Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Business Wire October 2, 2024

UroGen Receives New U.S. Patent Allowance for Next-Generation Mitomycin-Based Products Expected to Provide Protection Until December 2041

Business Wire September 16, 2024
View More News ››

Opinion & Analysis (NDAQ:URGN)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:URGN)

UroGen Pharma Ltd.: Positioning for Significant Growth with

http://beyondspx.com/2024/07/31/urogen-pharma-ltd-positioning-for-significant-growth-with-promising-pipeline-and-approved-product/
MikeTester - August 2, 2024

NextEra Energy, Lennar And Other Big Stocks Moving Lower In

Breaking News: $URGN NextEra Energy, Lennar And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session | BenzingaU.S. stock...
whytestocks - June 18, 2024

UroGen Pharma Announces Pricing of Public Offering of Ordina

Just In: $URGN UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded WarrantsUroGen Pharma Ltd. (Nasdaq...
whytestocks - June 17, 2024

URGN Price Target Alert: $40.00. Issued by Oppenheimer

Breaking News: $URGN URGN Price Target Alert: $40.00. Issued by Oppenheimer2024-06-14 09:00:10 ET Leland Gershell from Oppenheimer...
whytestocks - June 14, 2024

UroGen Pharma Ltd. (NASDAQ: URGN) Leading the Way in Thursda

Just In: $URGN UroGen Pharma Ltd. (NASDAQ: URGN) Leading the Way in Thursday Trading Based on Percentage GainUroGen Pharma Ltd. (NASDAQ:...
whytestocks - June 13, 2024
View more Bullboard ››

Voyageur Pharmaceuticals Ltd

Voyageur Pharmaceuticals Ltd

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical ...
View More »